Virginia 2026 Regular Session

Virginia Senate Bill SB706

Introduced
1/14/26  
Refer
1/14/26  
Report Pass
1/29/26  
Refer
1/14/26  
Engrossed
2/2/26  
Report Pass
1/29/26  
Engrossed
2/2/26  
Refer
2/9/26  
Report Pass
2/19/26  
Enrolled
2/26/26  
Chaptered
4/22/26  

Caption

An Act to amend the Code of Virginia by adding a section numbered 32.1-45.5, relating to Department of Health; opioid antagonist distribution program; reports.

Impact

The implications of SB706 are significant in the context of public health policy in Virginia. The legislation requires quarterly reporting to various committee chairs regarding the distribution of opioid antagonists, ensuring transparency and accountability in how these resources are allocated and utilized. Additionally, it mandates the development of a methodology to estimate the costs associated with the distribution program, which will aid in budgetary planning and resource allocation for future fiscal years.

Summary

SB706, known as the Opioid Antagonist Distribution Program, introduces a structured framework for the distribution of opioid antagonists, such as Naloxone, in Virginia. The bill mandates that the Virginia Department of Health maintain an accurate list of agencies and organizations that request and receive these life-saving medications. This proactive measure aligns with the state's ongoing efforts to combat the opioid epidemic and increase accessibility to emergency treatments for overdoses.

Sentiment

The sentiment surrounding SB706 appears to be largely supportive, as it is seen as a critical step towards addressing the opioid crisis. Legislative members and health advocates have expressed a consensus on the importance of making opioid antagonists readily available. This program could ultimately save lives, reduce overdose deaths, and foster a more health-conscious society. However, the implementation and effectiveness of the distribution program may become areas of future scrutiny.

Contention

While generally supported, some concerns have arisen regarding the potential for resource allocation disparities among different regions. The bill does not specify how the needs of diverse communities will be consistently assessed and met, which could lead to inequities in access to opioid antagonists. Additionally, ongoing evaluations of the program's effectiveness will be crucial to ensure that it meets its goals and adapts to emerging challenges in public health.

Companion Bills

No companion bills found.

Previously Filed As

VA SB1035

Opioid antagonists; dispensing and administration by person acting on behalf of an organization.

VA SB790

Opioid antagonists; dispensing and administration by person acting on behalf of an organization.

VA HB1637

Opioid antagonists; dispensing and administration by person acting on behalf of an organization.

VA SB1257

Student & campus safety; opioid antagonist administration training for resident assistants required.

VA HB1903

Virginia Health Workforce Development Authority; Virginia Nursing Workforce Center established; reporting and monitoring of health care workforce programs; residency slots; work group; report.

VA HB2269

Hospitals; reports of threats or acts of violence against health care providers.

VA SB1260

Hospitals; reports of threats or acts of violence against health care providers.

VA HB2170

Virginia Natural Resources Commitment Fund; distribution of certain funds, reports.

VA HB1902

Board of Health; Department of Health Professions; Prescription Monitoring Program; overdose information.

VA SB1322

Virginia Gaming Commerce Regulation Act; established, penalties distribution of funds, report.

Similar Bills

No similar bills found.